Kamada Plans Three More Biosimilar Launches In Israel
Post Approval, Company Expects Sales Of $5m-$7m From The Candidates
Executive Summary
Israeli firm Kamada has entered into two agreements for commercialization of three biosimilars in Israel. The company expects to launch the products between 2022 and 2024.